scispace - formally typeset
A

Amr H. Sawalha

Researcher at University of Pittsburgh

Publications -  215
Citations -  9674

Amr H. Sawalha is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Systemic lupus erythematosus & DNA methylation. The author has an hindex of 52, co-authored 188 publications receiving 7794 citations. Previous affiliations of Amr H. Sawalha include University of Oklahoma Health Sciences Center & United States Department of Veterans Affairs.

Papers
More filters
Journal ArticleDOI

COVID-19 and autoimmune diseases.

TL;DR: In this article, the authors evaluated the relationship between infection with SARS-CoV-2 and autoimmunity, focusing on similarities in immune responses, cross-reactivity of SARS and CoV2, the development of autoimmune diseases in COVID-19 patients, and the risk of infection in patients with preexisting autoimmune conditions.
Journal ArticleDOI

Genome-wide DNA methylation study suggests epigenetic accessibility and transcriptional poising of interferon-regulated genes in naïve CD4+ T cells from lupus patients

TL;DR: The data suggest epigenetic "poising" of interferon-regulated genes in l upus naïve CD4+ T cells, argue for a novel pathogenic implication for abnormal T cell DNA methylation in lupus, and suggest a mechanism for type-I interferons hyper-responsiveness in lUPus T cells.
Journal ArticleDOI

Genome-wide DNA methylation patterns in CD4+ T cells from patients with systemic lupus erythematosus

TL;DR: Data suggest that the methylation status of RAB22A, STX1B2, LGALS3BP, DNASE1L1 and PREX1 correlates with disease activity in lupus patients, and protein-protein interaction maps identified a transcription factor, HNF4a, as a regulatory hub affecting a number of differentially methylated genes.
Journal ArticleDOI

Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients.

TL;DR: It is suggested that patients with systemic lupus erythematous might be especially prone to severe COVID-19 independent of their immunosuppressed state from lupUS treatment, and Epigenetic control of the ACE2 gene might be a target for prevention and therapy in CO VID-19.